Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73144 | 0.89 | ALDH1A1 (0.54) | ALDH1A1PKMMMESLC1A2KMT2A | |
| SCHEMBL4381247 | 0.79 | ALDH1A1 (0.49) | ALDH1A1PKMMMESLC1A2KMT2A | |
| SCHEMBL9258688 | 0.76 | ALDH1A1 (0.61) | ALDH1A1PKMSLC1A2KMT2ACYP2C19 | |
| SCHEMBL987319 | 0.76 | MAPK1 (0.52) | ALDH1A1PKMMMEKMT2ACYP2C19 | |
| SCHEMBL988202 | 0.76 | MAPK1 (0.52) | ALDH1A1PKMMMEKMT2ACYP2C19 | |
| SCHEMBL698898 | 0.76 | ALDH1A1 (0.56) | ALDH1A1PKMMMESLC1A2KMT2A | |
| SCHEMBL2490385 | 0.76 | ALDH1A1 (0.45) | ALDH1A1PKMMMESLC1A2KMT2A | |
| SCHEMBL15623808 | 0.73 | ALDH1A1 (0.53) | ALDH1A1PKMMMESLC1A2CHRM2 | |
| SCHEMBL1269476 | 0.73 | ALDH1A1 (0.53) | ALDH1A1PKMMMESLC1A2KMT2A | |
| SCHEMBL9453802 | 0.73 | ALDH1A1 (0.53) | ALDH1A1PKMMMESLC1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322597-B1 | PROCESS AND INTERMEDIATES | GLAXOSMITHKLINE LLC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1322597-A4 | PROCESS AND INTERMEDIATES | SMITHKLINE BEECHAM CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6884874-B2 | Process and intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040014980-A1 | Such as n-methyl-alanine derivatives; for preparing antibody/maytansinoid complexes | SMITHKLINE BEECHAM PLC | 2004-01-22 | — | — | US | disclosed |
| EP-1322597-A1 | PROCESS AND INTERMEDIATES | SmithKline Beecham Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6570024-B2 | N-methyl-L-alanine derivatives derivatives used for preparing cell binding agent/maytansinoid complexes | SMITHKLINE BEECHAM CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020156318-A1 | Process and intermediates | GLAXOSMITHKLINE LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002022554-A1 | PROCESS AND INTERMEDIATES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| US-5395924-A | Oligosaccharide or glycopeptide bound to lectin and conjugated with cell binding agent, improved targeting of cells for cytolysis | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5239062-A | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014980-A1 | Such as n-methyl-alanine derivatives; for preparing antibody/maytansinoid complexes | HGFAC, ANPEP, AAAS | ALDH1A1 2103/4885PKM 2231/4885MME 122/4885 |
| US-20020156318-A1 | Process and intermediates | HGFAC, MTAP, SPR | ALDH1A1 2218/4885PKM 735/4885MME 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.